November 26, 2024
3.3 Anti-obesity medicine Anti-obesity medicine (AOM) options that are currently approved by the US Food and Drug Administration (FDA) include liraglutide, phentermine, phentermine/topiramate extended release (ER), naltrexone sustained release (SR) /bupropion sustained release (SR) and orlistat (52)
"Because regardless of whether they want to go to Ro or they want to go to their in-person doctor, you want to better understand what their options are."
Are you ready to boost your metabolism, burn fat, and achieve your weight loss goals
Peptide amount: 10 mg Water added: 2 ml Desired dose: 2.5 mg Concentration = 5 mg/ml Injection volume = 0.5 ml Syringe units (U-100) = 50 units This means: You need to draw 50 units in a U-100 insulin syringe for each 2.5 mg dose
It is generally considered well-tolerated, however, there have been some reports of mild irritation at the injection site or allergic reactions